11 November 2024
11 November 2024
Leqembi is approved for Alzheimer鈥檚 patients in multiple territories, but questions remain over its cost-effectiveness.
Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of AUR200.
A Phase III trial with the companies鈥� monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its primary endpoint.
Is the food industry producing patients for the pharmaceutical industry?
Sunvozertinib received BTDs from the FDA in April this year.
Experts in the neuropsychiatry drug development space say targeting the right patient population will be key for success in the field.
The approval by Health Canada is supported by the outcomes from the ConquerRSV Phase III study.
The PIKA rabies vaccine leverages LakeShore Biopharma's PIKA adjuvant technology.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
